Gusacitinib clinical trials
Also written ASN002.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses gusacitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ASN002
- 8
Studies by the year they started
10 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses gusacitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway InhibitorCompletedPhase 2Ascend Biopharmaceuticals LtdNCT04416516Written as ASN-002
- Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic DermatitisTerminatedPhase 2Asana BioSciencesNCT03654755Written as ASN002
- Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)CompletedPhase 2Asana BioSciencesNCT03531957Written as ASN002
- A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsTerminatedPhase 1/2Asana BioSciencesNCT02440685Written as ASN002 Dose Escalation
- A Study To Evaluate ASN002 In Subjects With Atopic DermatitisCompletedPhase 1Asana BioSciencesNCT03139981Written as ASN002
- Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand EczemaCompletedPhase 2Asana BioSciencesNCT03728504Written as ASN002
- Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy VolunteersCompletedPhase 1Asana BioSciencesNCT02853643Written as ASN002
- Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)SuspendedPhase 1/2Ascend Biopharmaceuticals LtdNCT03208296Written as ASN-002
- Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male SubjectsCompletedPhase 1Asana BioSciencesNCT03641573Written as [14C] ASN002
- A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell CarcinomaCompletedPhase 1/2Ascend Biopharmaceuticals LtdNCT02550678Written as ASN-002
Codes
What other systems call gusacitinib · ClinicalTrials.gg INT001332
- MeSH (NLM) C000707471gusacitinibConfirmed NLM, Wikidata
- UNII (FDA) 4801QYW816GUSACITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q105336942gusacitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166736GusacitinibOne source FDA
- DrugBank DB15670One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707471 | gusacitinib | Confirmed NLM, Wikidata |
| UNII (FDA) | 4801QYW816 | GUSACITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105336942 | gusacitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166736 | Gusacitinib | One source FDA |
| DrugBank | DB15670 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.